FY2024 EPS Estimates for Cingulate Lifted by Zacks Small Cap

Cingulate Inc. (NASDAQ:CING) – Equities researchers at Zacks Small Cap lifted their FY2024 earnings per share estimates for shares of Cingulate in a research report issued on Tuesday, November 12th. Zacks Small Cap analyst J. Vandermosten now expects that the company will post earnings per share of ($9.50) for the year, up from their previous estimate of ($16.00). The consensus estimate for Cingulate’s current full-year earnings is ($9.26) per share. Zacks Small Cap also issued estimates for Cingulate’s Q4 2024 earnings at ($1.49) EPS, FY2025 earnings at ($2.33) EPS and FY2026 earnings at ($0.27) EPS.

Cingulate (NASDAQ:CING) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.22) by $0.39.

Cingulate Price Performance

Shares of NASDAQ CING opened at $4.20 on Thursday. Cingulate has a 12-month low of $1.80 and a 12-month high of $152.40. The stock’s 50 day simple moving average is $4.70 and its 200 day simple moving average is $3.05.

Institutional Trading of Cingulate

A hedge fund recently bought a new stake in Cingulate stock. Armistice Capital LLC bought a new stake in shares of Cingulate Inc. (NASDAQ:CING) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 490,000 shares of the company’s stock, valued at approximately $157,000. Armistice Capital LLC owned approximately 6.67% of Cingulate at the end of the most recent reporting period. Institutional investors and hedge funds own 41.31% of the company’s stock.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.